ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.
about
The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cellsSpotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectivesMolecular Targeted Therapies of Aggressive Thyroid CancerThe treatment landscape in thyroid cancer: a focus on cabozantinibOverview and management of dermatologic events associated with targeted therapies for medullary thyroid cancerMedical management of metastatic medullary thyroid cancerWill the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies.Recent Updates on the Management of Medullary Thyroid CarcinomaThe interplay between obesity and cancer: a fly viewErbB polymorphisms: insights and implications for response to targeted cancer therapeuticsVandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport functionIncidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysisMET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC CellsPhase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancerComputational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability.The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity.Medullary thyroid carcinoma: targeted therapies and future directionsMy, How Things Have Changed in Multiple Endocrine Neoplasia Type 2A!Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma.Thyroid cancer: current molecular perspectives.Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.Multi-targeted approach in the treatment of thyroid cancer.Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancerOld and new insights in the treatment of thyroid carcinoma.Immune response in thyroid cancer: widening the boundaries.Signaling mechanisms in neuroendocrine tumors as targets for therapy.A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy.Kinome sequencing reveals RET G691S polymorphism in human neuroendocrine lung cancer cell lines.Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas.Efficacy and safety profile of combining vandetanib with chemotherapy in patients with advanced non-small cell lung cancer: a meta-analysis.Medullary thyroid carcinoma: molecular signaling pathways and emerging therapiesVandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort studyThe oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report.The multi-targeted tyrosine kinase inhibitor vandetanib plays a bifunctional role in non-small cell lung cancer cells.Targeted treatment of differentiated and medullary thyroid cancer.ZEPHYR: failure of a "spring wind" in lung cancer.
P2860
Q24519206-0B6CC20A-86BA-4B6B-A483-29439390421EQ26751274-D55C77FF-D7B5-411C-9A6D-FB3C633BDCE8Q26774734-88783EF5-4CC6-467F-B6DD-F6D51C454DCCQ26796404-CBE3D796-D271-41FA-B0BD-87B8DAA6C101Q27005701-097C2A85-FDC9-4A40-BE53-9A581144C445Q27005897-8A484405-762D-4131-B56F-AF9F21947D9DQ27023383-3D1444ED-87CB-4AB7-9ABE-DFB6E2C2D629Q27692050-D3E209B6-BB01-49A3-8CEF-F088D3365B20Q28066911-13400115-35D1-4935-B25D-56C7EA25AAAAQ28079088-87445C56-D4CF-4487-A8FC-E54F075FA21AQ28084565-08976588-1E55-458C-8F01-67E31C575B3DQ28475378-A842702A-7FEA-4C67-A5E7-63A60081BA8AQ28480930-15DA7F51-7446-44A2-81EA-5BD31E8D92DFQ28551045-F6B9C0CF-B539-494F-918C-F92A50407D0AQ28728593-92517DF1-0ED2-428B-90E4-ED3943B6E023Q30374663-DD5E9F9D-0A2D-4E3E-B9AC-B3F0F9A6E026Q30381368-B216DF2F-7DFD-44C3-8903-3996D32A1347Q33557376-9A13D3B5-DBA6-407B-8AFB-92770399CDE3Q33570313-D3631169-9A47-412C-9096-2CCE3AA39F11Q33710562-141B124A-FC0C-4F52-9AFC-A940CF00F7C6Q33757079-B81E18C7-3BEA-4BDE-8742-97F0E6015CEFQ33760910-B99D0AFF-D091-406B-842A-6B73CFEAA505Q33903078-EBB874FD-FC50-43A5-8CD2-68DF1A3C37ABQ33982413-FE8883A9-2670-408D-A3FC-A7602D5D61B8Q33984845-2D16F600-2A24-4226-8205-80D8CFBD5560Q34209934-2C416F94-B815-4FF4-812B-8E5821878261Q34310495-7F1A34DD-A5D9-4588-B543-597E506E4B7EQ34447484-8EED1773-7E58-425C-95F6-DAA8FA86D5EEQ34618606-72A5685B-F2CA-4B63-8A36-A7B37206FF57Q34729370-D21CB836-F537-4722-9BEE-6715B1DC47E9Q34757990-009794A0-98A0-48E6-95C0-808A6053696DQ34765380-636896B5-0615-42AF-BFED-E136C502A1A3Q34826532-35B85653-DF45-4144-A763-B5983A8BA81DQ35038893-66994870-78EC-4F67-B842-085B3DFA1960Q35071684-2AF1A853-CB47-4A55-B1DE-153DF1CB3081Q35103009-42C7AA44-F070-46EA-A04A-6B4DCFFF936FQ35108522-9D583F43-8AC7-42CD-8947-51DE9FD3F0B2Q35126928-7563D056-8408-404D-BE31-9214992F42EFQ35147151-DFBFD13A-0ED0-46AC-8F42-46C051D929DAQ35200470-DE7F4AA2-4BBC-415B-9121-8155E5EB5A1A
P2860
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
ZD6474, an orally available in ...... blocks oncogenic RET kinases.
@ast
ZD6474, an orally available in ...... blocks oncogenic RET kinases.
@en
ZD6474, an orally available in ...... blocks oncogenic RET kinases.
@nl
type
label
ZD6474, an orally available in ...... blocks oncogenic RET kinases.
@ast
ZD6474, an orally available in ...... blocks oncogenic RET kinases.
@en
ZD6474, an orally available in ...... blocks oncogenic RET kinases.
@nl
prefLabel
ZD6474, an orally available in ...... blocks oncogenic RET kinases.
@ast
ZD6474, an orally available in ...... blocks oncogenic RET kinases.
@en
ZD6474, an orally available in ...... blocks oncogenic RET kinases.
@nl
P2093
P50
P1433
P1476
ZD6474, an orally available in ...... y blocks oncogenic RET kinases
@en
P2093
Alfredo Fusco
Anderson J Ryan
Donata Vitagliano
Francesca Carlomagno
Giancarlo Vecchio
Massimo Santoro
Teresa Guida
P304
P407
P577
2002-12-01T00:00:00Z